1. |
2. |
3. |
4. CA19-9 serum levels predict micrometastases in patients with gastric cancerTomaž Jagrič, Stojan Potrč, Katarina Miš, Mojca Plankl, Tomaž Marš, 2016, izvirni znanstveni članek Povzetek: Background. We explored the prognostic value of the up-regulated carbohydrate antigen (CA19-9) in node-negative patients with gastric cancer as a surrogate marker for micrometastases. Patients and methods. Micrometastases were determined using reverse transcription quantitative polymerase chain reaction (RT-qPCR) for a subgroup of 30 node-negative patients. This group was used to determine the cut-off for preoperative CA19-9 serum levels as a surrogate marker for micrometastases. Then 187 node-negative T1 to T4 patients were selected to validate the predictive value of this CA19-9 threshold. Results. Patients with micrometastases had significantly higher preoperative CA19-9 serum levels compared to patients without micrometastases (p = 0.046). CA19-9 serum levels were significantly correlated with tumour site, tumour diameter, and perineural invasion. Although not reaching significance, subgroup analysis showed better five-year survival rates for patients with CA19-9 serum levels below the threshold, compared to patients with CA19-9 serum levels above the cut-off. The cumulative survival for T2 to T4 node-negative patients was significantly better with CA19-9 serum levels below the cut-off (p = 0.04). Conclusions. Preoperative CA19-9 serum levels can be used to predict higher risk for haematogenous spread and micrometastases in node-negative patients. However, CA19-9 serum levels lack the necessary sensitivity and specificity to reliably predict micrometastases.
Ključne besede: gastric cancer, micrometastases, CA19-9, rak (medicina), želodec, metastaze, diagnostika, antigeni, tumorski označevalci
Objavljeno v DiRROS: 09.05.2024; Ogledov: 165; Prenosov: 146
 Celotno besedilo (793,76 KB)
Gradivo ima več datotek! Več... |
5. Pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head with venous resectionVojko Flis, Stojan Potrč, Nina Kobilica, Arpad Ivanecz, 2016, izvirni znanstveni članek Povzetek: Background. Recent reports have shown that patients with vascular tumour invasion who undergo concurrent vascular resection can achieve long-term survival rates equivalent to those without vascular involvement requiring pancreaticoduodenectomy alone. There is no consensus about which patients benefit from the portal-superior mesenteric vein resection and there is no consensus about the best surgical technique of vessel reconstruction (resection with or without graft reconstruction). As published series are small the aim of this study was to evaluate our experience in pancreatectomies with en bloc vascular resection and reconstruction of vessels. Methods. Review of database at University Clinical Centre Maribor identified 133 patients (average age 65.4 +/- 8.6 years, 69 female patients) who underwent pancreatoduodenectomy between January 2006 and August 2014. Clinical data, operative results, pathological findings and postoperative outcomes were collected prospectively and analyzed. Current literature and our experience in pancreatectomies with en bloc vascular resection and reconstruction of portal vein are reviewed. Results. Twenty-two patients out of 133 (16.5 %) had portal vein-superior mesenteric vein resection and portal vein reconstruction (PVR) during pancreaticoduodenectomy. In fourteen patients portal vein was reconstructed without the use of synthetic vascular graft. In these series two types of venous reconstruction were performed. When tumour involvement was limited to the superior mesenteric vein (SPV) or portal vein (PV) such that the splenic vein could be preserved, and vessels could be approximated without tension a primary end-to-end anastomosis was performed. When tumour involved the SMV-splenic vein confluence, splenic vein ligation was necessary. In the remaining eight procedures interposition graft was needed. Dacron grafts with 10 mm diameter were used. There was no infection after dacron grafting. One patient had portal vein thrombosis after surgery: it was thrombosis after primary reconstruction. There were no thromboses in patients with synthetic graft interposition. There were no significant differences in postoperative morbidity, mortality or grades of complication between groups of patients with or without a PVR. Median survival time in months was in a group with vein resection 16.13 months and in a group without vein resection 15.17 months. Five year survival in the group without vein resection was 19.5%. Comparison of survival curves showed equal hazard rates with log-rank p = 0.090. Conclusions. Survival of patients with pancreatic cancer who undergo an R0 resection with reconstruction was comparable to those who have a standard pancreaticoduodenectomy with no added mortality or morbidity. Synthetic graft appeared to be an effective and safe option as an interposition graft for portomesenteric venous reconstruction after pancreaticoduodenectomy.
Objavljeno v DiRROS: 09.05.2024; Ogledov: 128; Prenosov: 105
Celotno besedilo (572,34 KB)
Gradivo ima več datotek! Več... |
6. Priporočila za obravnavo bolnikov z rakom debelega črevesa in danke2020, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Ključne besede: rak debelega črevesa, rak danke, bolniki, zdravljenje
Objavljeno v DiRROS: 18.03.2022; Ogledov: 949; Prenosov: 521
Celotno besedilo (1,30 MB)
Gradivo ima več datotek! Več... |
7. Slovenska priporočila za obravnavo odraslih bolnikov s kronično odpovedjo prebavilNada Rotovnik-Kozjek, Tajda Božič, Katja Kogovšek, Borut Štabuc, Laura Petrica, Karla Berlec, Nataša Puzić Ravnjak, Erik Brecelj, Aleš Tomažič, Sanela Banović, Rada Franko, Milena Kovač-Blaž, Janez Breznik, Davorin Ćeranić, David Drobne, Mojca Gašperin, Tomaž Jurca, Maja Ebert Moltara, Rado Janša, Marjana Turk Jerovšek, Taja Jordan, Tina Kamhi, Primož Karner, Milena Kerin-Povšič, Neža Majdič, Denis Mlakar-Mastnak, Andreja Ocepek, Tadeja Pintar, Stojan Potrč, Nataša Smrekar, Monika Sonc, Maja Šeruga, Petra Tavčar, Igor Virant, 2021, strokovni članek Ključne besede: kronična odpoved prebavil, zdravljenje, onkološko zdravljenje
Objavljeno v DiRROS: 11.06.2021; Ogledov: 1486; Prenosov: 393
Celotno besedilo (135,03 KB) |
8. Hepatocelični rak - možnost resekcije jeterArpad Ivanecz, Marko Sremec, Tomaž Jagrič, Stojan Potrč, 2014, izvirni znanstveni članek Povzetek: Resekcija jeter (RJ) je ostala glavna oblika terapije pri solitarnem hepatoceličnem raku (HCC), pri bolnikih z ohranjeno funkcijsko rezervo jeter in v primernem splošnem stanju. Izpopolnjene slikovne preiskave so pripomogle k boljši izbiri bolnikov. Kirurgija jeter je napredovala: uporabne so številne tehnike transekcije jetrnega tkiva; dosegljive so različne naprave, ki omogočajo hitrejše in natančnejše operiranje v brezkrvnem operativnem polju. Izboljšana kirurška tehnika, vzdrževanje nizkega centralnega venskega pritiska in napredek pri negi bolnika po operaciji so omogočili, da se je smrtnost po operaciji jeter v izbranih serijah znižala celo do 0%. Barcelona Clinic Liver Cancer (BCLC) klasifikacija poleg zamejitve bolezni, nudi priporočila tudi glede izbora terapije. Kirurško terapijo omejuje zgolj na bolnike z zgodnjim stadijem raka. Namen tega prispevka je raziskati, ali je v sedanjem času mogoče RJ opraviti s sprejemljivimi kratko- in dolgoročnimi rezultati tudi pri bolnikih s takšnim HCC, pri katerem so prisotni številni in veliki tumorji, ki makroskopsko vdirajo v žile.
Ključne besede: jetra, hepatocelični rak, resekcija, kirurški postopki, operativni, zapleti, smrtnost, preživetje
Objavljeno v DiRROS: 08.12.2020; Ogledov: 1437; Prenosov: 711
Celotno besedilo (520,99 KB)
Gradivo ima več datotek! Več... |
9. Smernice za obravnavo bolnikov z rakom debelega črevesa in dankeFranc Anderluh, Jernej Benedik, Erik Brecelj, Ibrahim Edhemović, Eldar Gadžijev, Zvezdana Hlebanja, Irena Oblak, Janja Ocvirk, Martina Reberšek, Marija Skoblar Vidmar, Matjaž Šušteršič, Vaneja Velenik, Neva Volk, Mirko Omejc, Franc Jelenc, Stojan Potrč, Miran Koželj, 2011, objavljeni strokovni prispevek na konferenci Objavljeno v DiRROS: 17.09.2019; Ogledov: 2700; Prenosov: 672
Celotno besedilo (157,00 KB) |
10. Rak želodca : kaj morate vedeti o bolezniJanja Ocvirk, Stojan Potrč, Franc Anderluh, Irena Oblak, Martina Reberšek, Vaneja Velenik, 2011, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid Povzetek: “Kaj morate vedeti o bolezni ?” je podnaslov te publikacije. Zato boste v njej našli odgovore o nastanku te te bolezni, kot tudi znakih in simptomih, diagnostiki, ter zdravljenju, in še veliko več.
Ključne besede: dejavniki tveganja, simptomi, diagnostika, zdravljenje
Objavljeno v DiRROS: 25.03.2019; Ogledov: 2409; Prenosov: 680
Celotno besedilo (777,88 KB) |
